"ohh a competitor with a Gen 1 tech is $3B and CYP is only $50M.... a $500M TO would be a steal"
1. To be considered a competitor, Cyanta would have to have a FDA approval. Or any approval. Or maybe have completed a single P3, even. 2. Gen 1 with FDA approval is better than Gen (whatever) with little hope. 3. If Cynata goes broke the market cap is not relevant.
How is it that shareholders of both MSB and CYP never want to look at management to do better and will ridiculously and relentlessly argue to have them continue to not deliver much of anything they say they are going to? It's bizarre.
CYP Price at posting:
23.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)